Clinical Trial Search

Primary: Seroconversion Following 3 Doses of 9-valent HPV Vaccines — 100; 64.2; 100; 70.7 Percentage of participants

Primary: CD4+ Level — 162.3; 50.5; 143.3; 69.9 cell/μL — p=0.02

Primary: Number of Participants With SAEs — 0; 0; 2; 0 Participants

Primary: Percentage of Participants With Non-Relapse Mortality — 0.0; 11.8; 18.3 percentage of participants

Primary: Number of Participants With Composite Safety Endpoint of the Occurrence of Serious Adverse Events (SAEs) or Division of AIDS (DAIDS) Grade 3 and 4 Signs and Symptoms…

Primary: Number and Percentage of Participants With Anti-HBs Seroconversion at Month 7 — 75; 69 Participants

Primary: Grade 3 or Higher Adverse Events Through 24 Weeks — 13; 10 Participants — p=0.40

Primary: Symptom Score — 10; 8 units on a scale — p=0.45

Primary: Number of Patients Alive at 2 Years Without Recurrent Brain Lymphoma or Severe Neurocognitive Defects — 8 Participants

Primary: Number of Participants With New or Recurrent AIDS Event, or Death — 83; 82 participants — p=0.69

Primary: Progression to AIDS or Death in tx naïve Pts With Adv HIV dx in the Four Randomly Assigned Regimens. — 93; 77; 70; 80 participants

Primary: Median Progression Free Survival (PFS) — 13.8 years

Primary: Safety — 22; 3; 0; 18 percentage of participants

Primary: Levels of Proviral DNA in Peripheral Blood Mononuclear Cells (PBMC) (log10) — 1.88; 1.92 log10(copies/mL)

Primary: Change From Baseline in HIV DNA in PBMCs at Week 56 — 0.00; 0.04 log^10 copies per 10^6 PBMCs

Primary: All-cause Mortality — 21; 18 participants

Primary: Proportion of Patients With Treatment-emergent Adverse Events, Serious Adverse Events, and Adverse Events of Specific Interest — 28; 27; 3; 3 Participants

Primary: CD4/CD8 Ratio — 0.44 Ratio

Primary: Primary Outcome Measure — 1; 2 Participants

Primary: New or Recurrent Disease Progression Events, as Defined, or Death. — 110; 119 Participants — p=0.47

Primary: Week 24 Change in Percentage of CD8+ T Cells That Co-express CD38 and HLA DR (Week 24 %CD38+HLA-DR+ CD8+ T Cells Minus Baseline %CD38+HLA-DR+ CD8+ T Cells) — 2.2; -0.7…

Primary: Number of Participants Who Discontinued Study-provided High Dose Fluconazole or Ampho B — 14; 11; 11; 6 Participants — p=0.0012

Primary: Part A: To Establish Highest Tolerated Dose of Lenalidomide, Dose-Limiting Toxicity — 0; 0; 0 Participants

Primary: Immunoglobulin G (IgG) Levels — 5.12; 5.17; 1.80; 1.83 Micrograms/ml

Primary: Immunogenicity — 22; 25; 344; 686 Geometric Mean antibody titer

Primary: Number of Events of ALT Elevation After Baseline, Controlling for APRI Score and Other Variables — 9; 4 events — p=0.02

Primary: Pre- and Post- Interferon Alpha on Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) — 670; 180; 90; 130 # of copies of HIV RNA/million cells

Primary: Overall Survival — 0; 0 Proportion of participants

Primary: Baseline-Adjusted Means for C-terminal Telopeptide of Collagen (CTx) Levels — 0.092; 0.297; 0.122; 0.331 ng/ml

Primary: Muscle Glutathione Concentration — 0.5; 2.2 micromol/g.Hb